Eli Lilly | LLY - Net Income


Eli Lilly reported $7.1B in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
AbbVie USD 4.22B 605M Sep/2026
Abbott USD 920M 8M Sep/2026
ALKERMES USD 16.29M 15.79M Sep/2026
Amgen USD 3.86B 1.49B Sep/2026
AstraZeneca USD 3.12B 610M Sep/2026
Baxter International USD 294M 168M Sep/2026
Biogen USD 97.5M 222M Jun/2026
Bristol-Myers Squibb USD 2.16B 1.16B Sep/2026
Coherus Biosciences USD -37.64M 2.11M Dec/2025
Drreddys Laboratories INR 9.25B 7.04B Sep/2026
Eli Lilly USD 7.1B 301M Jun/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
GlaxoSmithKline GBP 1.54B 1.11B Sep/2026
Glaxosmithkline GBP 1.54B 194M Sep/2026
J&J USD 210M 5.32B Sep/2026
Medtronic USD 1.47B 227M Jun/2026
Merck USD 5.07B 6.4B Sep/2026
Neurocrine Biosciences USD 206.5M 62.1M Sep/2026
Novartis USD 1.2B 2.06B Sep/2026
Novartis USD 1.2B 1.95B Sep/2026
Novo Nordisk DKK 20.99B 5.9B Jun/2026
Perrigo USD -27.5M 102M Sep/2026
Pfizer USD 3.24B 3.49B Sep/2026
Phibro Animal Health USD 27.46M 932K Dec/2025
Prestige Brands USD 38.54M 15.39M Jun/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sanofi EUR 3.02B 2.68B Sep/2026
Sanofi EUR 343M 1.27B Jun/2026
United Therapeutics USD 258.6M 74.4M Sep/2026
Zoetis USD 591M 100M Sep/2026